Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 16/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 16/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 16/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.67 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037203 | 0.86 | HDAC6 (0.52) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL19535082 | 0.86 | HDAC8 (0.62) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18625972 | 0.82 | HDAC8 (0.58) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL17037191 | 0.82 | HDAC3 (0.66) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL17037196 | 0.81 | ALOX5 (0.53) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL17037206 | 0.81 | HDAC3 (0.48) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL17040251 | 0.81 | HDAC3 (0.68) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL17037208 | 0.80 | HDAC8 (0.50) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL16264702 | 0.79 | HDAC8 (0.54) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL21286389 | 0.79 | HDAC8 (0.55) | HDAC8HDAC6HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376385-B2 | Solid-phase supports and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376385-B2 | Solid-phase supports and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150240006-A1 | Solid-Phase Supports and Uses Thereof | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-20150240006-A1 | Solid-Phase Supports and Uses Thereof | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240006-A1 | Solid-Phase Supports and Uses Thereof | ACR, ALK, ALKBH3 | HDAC8 4009/4885HDAC6 3236/4885HDAC3 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.